Synthonix and the Swiss Company SpiroChem Join Forces
March 23rd, 2012
Wake Forest based Synthonix. Inc. and the Swiss company SpiroChem AG today announced that they have forged a strategic partnership for the distribution of new SpiroChem products in the United States. With Prof. Erick Carreira as a co-founder, SpiroChem AG is a Swiss fine chemicals company active in the field of new, innovative value-added building blocks for the pharmaceuticals, agrochemicals and materials science. SpiroChem designs, synthesizes and commercializes a wide range of oxetane, azetidine, spirocyclic molecules for use as modules in drug discovery. Dr. Thomas Fessard, co-founder and CEO of SpiroChem, stated “I am convinced that the success of oxetanes is just the tip of the iceberg in efforts to identify new modules for drug discovery. We are committed to being the reliable partner and supplying the very latest high quality building blocks to the research community in a timely manner. The Synthonix/SpiroChem collaboration ensures that these innovative building blocks become essential components of cutting-edge research programs.” Gary Allred, President of Synthonix, said “We are extremely excited to have the opportunity to join forces with SpiroChem. We have been following the groundbreaking publications of Prof. Carreira for several years and many of our newer products are based on his publications. SpiroChem’s innovative products are already having a large impact in medicinal chemistry, and this partnership allows us to make these unique building blocks more readily available to our customer base.” Founded in 2003, Synthonix is focused on the synthesis of progressive building blocks and is committed to providing superior quality and customer service to medicinal chemistry researchers.